

# John R Prensner

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5757597/john-r-prensner-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37  
papers

10,348  
citations

31  
h-index

39  
g-index

39  
ext. papers

11,937  
ext. citations

22  
avg, IF

5.86  
L-index

#	Paper	IF	Citations
37	The landscape of long noncoding RNAs in the human transcriptome. <i>Nature Genetics</i> , <b>2015</b> , 47, 199-208	36.3	1789
36	The mutational landscape of lethal castration-resistant prostate cancer. <i>Nature</i> , <b>2012</b> , 487, 239-43	50.4	1708
35	The emergence of lncRNAs in cancer biology. <i>Cancer Discovery</i> , <b>2011</b> , 1, 391-407	24.4	1384
34	Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. <i>Nature Biotechnology</i> , <b>2011</b> , 29, 742-9	44.5	824
33	Role of the TMPRSS2-ERG gene fusion in prostate cancer. <i>Neoplasia</i> , <b>2008</b> , 10, 177-88	6.4	522
32	The long noncoding RNA SCHLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. <i>Nature Genetics</i> , <b>2013</b> , 45, 1392-8	36.3	515
31	Beyond PSA: the next generation of prostate cancer biomarkers. <i>Science Translational Medicine</i> , <b>2012</b> , 4, 127rv3	17.5	313
30	Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 913-25	27.4	257
29	Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer. <i>Cancer Research</i> , <b>2008</b> , 68, 73-80	10.1	212
28	PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. <i>Cancer Research</i> , <b>2014</b> , 74, 1651-60	10.1	204
27	PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma. <i>Cancer Research</i> , <b>2012</b> , 72, 1608-13	10.1	203
26	Expressed pseudogenes in the transcriptional landscape of human cancers. <i>Cell</i> , <b>2012</b> , 149, 1622-34	56.2	203
25	RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SCHLAP1. <i>Lancet Oncology, The</i> , <b>2014</b> , 15, 1469-1480	21.7	192
24	The long non-coding RNA PCAT-1 promotes prostate cancer cell proliferation through cMyc. <i>Neoplasia</i> , <b>2014</b> , 16, 900-8	6.4	187
23	Coordinated regulation of polycomb group complexes through microRNAs in cancer. <i>Cancer Cell</i> , <b>2011</b> , 20, 187-99	24.3	176
22	Modulation of long noncoding RNAs by risk SNPs underlying genetic predispositions to prostate cancer. <i>Nature Genetics</i> , <b>2016</b> , 48, 1142-50	36.3	158
21	Oncogenic Role of THOR, a Conserved Cancer/Testis Long Non-coding RNA. <i>Cell</i> , <b>2017</b> , 171, 1559-1572.e302	30.2	153

20	The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression. <i>Nature Communications</i> , <b>2016</b> , 7, 12791	17.4	152
19	Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. <i>Genome Research</i> , <b>2011</b> , 21, 1028-41	9.7	144
18	Targeting the MLL complex in castration-resistant prostate cancer. <i>Nature Medicine</i> , <b>2015</b> , 21, 344-52	50.5	126
17	The landscape of antisense gene expression in human cancers. <i>Genome Research</i> , <b>2015</b> , 25, 1068-79	9.7	110
16	The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 1081-7	6.6	103
15	The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. <i>Oncotarget</i> , <b>2014</b> , 5, 1434-8	3.3	84
14	Characterization of KRAS rearrangements in metastatic prostate cancer. <i>Cancer Discovery</i> , <b>2011</b> , 1, 35-43	24.4	83
13	A novel RNA in situ hybridization assay for the long noncoding RNA SCHLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. <i>Neoplasia</i> , <b>2014</b> , 16, 1121-7	6.4	71
12	KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. <i>Journal of Thoracic Oncology</i> , <b>2014</b> , 9, 1513-22	8.9	67
11	An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. <i>Nature Biotechnology</i> , <b>2009</b> , 27, 1005-11	44.5	63
10	Oncogenic gene fusions in epithelial carcinomas. <i>Current Opinion in Genetics and Development</i> , <b>2009</b> , 19, 82-91	4.9	60
9	Reconstructing targetable pathways in lung cancer by integrating diverse omics data. <i>Nature Communications</i> , <b>2013</b> , 4, 2617	17.4	54
8	Precision medicine in pediatric oncology: Lessons learned and next steps. <i>Pediatric Blood and Cancer</i> , <b>2017</b> , 64, e26288	3	51
7	Systematic, evidence-based discovery of biomarkers at the NCI. <i>Clinical and Experimental Metastasis</i> , <b>2012</b> , 29, 645-52	4.7	21
6	Noncanonical open reading frames encode functional proteins essential for cancer cell survival. <i>Nature Biotechnology</i> , <b>2021</b> , 39, 697-704	44.5	17
5	Clinically Integrated Sequencing Alters Therapy in Children and Young Adults With High-Risk Glial Brain Tumors. <i>JCO Precision Oncology</i> , <b>2018</b> , 2,	3.6	7
4	A community-driven roadmap to advance research on translated open reading frames detected by Ribo-seq		4
3	Non-canonical open reading frames encode functional proteins essential for cancer cell survival		2

2 A FIRE-y PAGE in the computational analysis of cancer profiles. *Molecular Cell*, **2009**, 36, 732-3 17.6

1 A case of metastatic adenocarcinoma of unknown primary in a pediatric patient: Opportunities for precision medicine. *Pediatric Blood and Cancer*, **2021**, 68, e28780 3